R&D Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal... Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
News SEC charges Cassava over 'misleading' Alzheimer's claims The US financial regulator has accepted a $40 million-plus settlement from Cassava Sciences and two of its former executives for making what it alleges are misleading statements about the r
News Pfizer elevates Chris Boshoff to top R&D role Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
